These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22123285)

  • 1. Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient.
    Katgi A; Ataca P; Kahraman S; Pişkin O; Ozcan MA; Demirkan F; Ozsan GH; Undar B
    Blood Coagul Fibrinolysis; 2012 Jan; 23(1):69-70. PubMed ID: 22123285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry.
    Ma AD; Kessler CM; Al-Mondhiry HA; Gut RZ; Cooper DL
    Haemophilia; 2016 Jan; 22(1):e18-24. PubMed ID: 26551409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
    Abshire T; Kenet G
    Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa in joint and muscle bleeding episodes.
    Bech RM
    Haemostasis; 1996; 26 Suppl 1():135-8. PubMed ID: 8904188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.
    Puetz J
    Drug Des Devel Ther; 2010 Jul; 4():127-37. PubMed ID: 20689699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia.
    Abshire T
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S3-6. PubMed ID: 18544421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of recombinant factor VIIa in hereditary bleeding disorders.
    Poon MC
    Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
    O'Connell KA; Wood JJ; Wise RP; Lozier JN; Braun MM
    JAMA; 2006 Jan; 295(3):293-8. PubMed ID: 16418464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VII therapy in acquired hemophilia of the elderly.
    Dragani A; Di Bartolomeo E; La Barba G; Cavoni A; Lanzillotta P; Guizzardi G; Davì G
    Aging Clin Exp Res; 2004 Dec; 16(6):487-9. PubMed ID: 15739602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
    Baudo F; de Cataldo F; Gaidano G;
    Haematologica; 2004 Jun; 89(6):759-61. PubMed ID: 15194550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIIa in the treatment of haemophilia.
    Hedner U
    Blood Coagul Fibrinolysis; 1990 Aug; 1(3):307-17. PubMed ID: 2103315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with activated factor VII: focus on safety aspects.
    Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with recombinant factor VIIa.
    Lusher J; Ingerslev J; Roberts H; Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9(2):119-28. PubMed ID: 9622209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
    Stewart AJ; Hanley JP; Ludlam CA
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
    Tiede A; Worster A
    Ann Hematol; 2018 Oct; 97(10):1889-1901. PubMed ID: 29804265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Neufeld EJ; Saxena K; Kessler CM; Cooper DL;
    Pediatr Blood Cancer; 2013 Jul; 60(7):1178-83. PubMed ID: 23335449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of using recombinant factor VIIa in continuous infusion.
    Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
    Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.